Future research should strive to conduct larger-scale, multicenter, randomized controlled trials to more accurately assess the efficacy and safety of SGLT-2 inhibitors in patients with various types of HF and T2DM. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.